Market

The total income from operation for the quarter ending September 2022 reported at Rs 146.30 crore, higher by 12.54 per cent over…

Operating revenue at Rs 452.6 crore, increased 25.5 per cent YoY, driven by a growth in the existing products as well as market…

Operating EBITDA grew by 44 per cent to Rs 202 crore

The company now expects annual revenue to be near the low end of its prior forecast range of between $2 billion and $2.3 billion

Revenue from operation grew by 11 per cent to Rs 3,202 crore versus Rs 2,889 crore in H1FY22

Pharma revenue up 50 per cent with expanding contribution from Latin America

The drug major also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further…

The industry reported 102 Venture Capital (VC) deals worth $1.8 billion in October 2022, compared to the last 12-month average…

The company has achieved the highest quarterly sales in its history

The company did say the 2023 outlook excludes expected contracts with countries such as the US and Japan, and that it anticipated…